인투셀

287840· KOSDAQ· Health Care· Pharmaceuticals, Biotechnology & Life Sciences

₩18,610+8.58%

2026-08-04

Financials

Valuation Metrics

인투셀's Market Cap is ₩2796B. At end of 2025 it was ₩8623B. Ranked #662 of 2,436 in KR market (top 27%), #268 of 1,649 on KOSDAQ (top 16%), #75 of 234 in Pharmaceuticals, Biotechnology & Life Sciences (top 32%) by Market Cap.

Investment Metrics(as of 2026-08-04)

Metric	Value	Rank
Size
Market Cap	279.56B KRW	KR#662/2,436 Sec#75/234
Revenue	2.47B KRW	KR#2,384/2,436 Sec#213/234
Net Income	-11.24B KRW	KR—/2,436 Sec—/234
Total Assets	38.64B KRW	KR#2,278/2,436 Sec#210/234
Net Assets	21.28B KRW	KR#2,263/2,436 Sec#213/234
Employees	41	KR#2,101/2,436 Sec#193/234
Value
P/B	13.14x	KR#2,368/2,436 Sec#213/234
P/S	113.13x	KR#2,392/2,436 Sec#213/234
FCF Yield	-3.14%	KR—/2,436 Sec—/234
Profitability
ROE	-52.83%	KR#2,276/2,436 Sec#201/234
ROA	-29.10%	KR#2,292/2,436 Sec#195/234
Op. Margin	-421.76%	KR#2,370/2,436 Sec#204/234
Revenue Growth	157.55%	KR#84/2,436 Sec#14/234
Financial Health
Debt Ratio	181.54%	KR#1,546/2,436 Sec#175/234
Total Debt	10.00B KRW	KR#1,624/2,436 Sec#147/234
FCF	-8.77B KRW	KR#1,670/2,436 Sec#141/234
Cash	8.62B KRW	KR#1,754/2,436 Sec#148/234
Current Ratio	6.92x	KR#187/2,436 Sec#42/234
Performance
1Y Return	-23.73%	KR#1,389/2,436 Sec#119/234
1M Return	-15.41%	KR#2,032/2,436 Sec#201/234
From 52W High	-75.15%	KR#2,280/2,436 Sec#212/234
1Y MDD	-80.49%	KR#2,305/2,436 Sec#214/234
Trading
Volume	83,618 shares	KR#1,043/2,436 Sec#99/234
Foreign Own.	3.98%	KR—/2,436 Sec—/234
Per Share
EPS	-764 KRW	KR—/2,436 Sec—/234
BPS	1,417 KRW	KR#2,184/2,436 Sec#192/234

Company Info

CEO 박태교

Employees 41

Founded 2015

HQ 대전광역시 대덕구, KR

Website intocell.com

동사는 2015년 약물접합체 기반 바이오신약기술 연구 및 개발을 목적으로 설립되어, 2025년 코스닥시장에 상장함. 항체-약물접합체(ADC) 분야에서 독자적인 OHPAS 링커플랫폼과 PMT 플랫폼 기술을 보유하며, 고유 약물기술을 개발 중임. 링커 플랫폼기술을 이용한 기술수출과 ADC 파이프라인으로 매출을 확보하고, ADC 분야에서 차별화된 솔루션을 제공하고 있음. 인투셀는 2015년에 설립되었으며 대전광역시 대덕구에 본사를 두고 있습니다.